RxDoctor Payments Data

Emma Abbey, NP

Nurse Practitioner · Tucson, AZNPI 1548822562

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 44 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$274
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$216
  • Intercept Pharmaceuticals, Inc.$205
  • Intra-sana Laboratories$129
  • Exact Sciences$62
  • Ipsen Biopharmaceuticals, Inc$53
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$94990%
  • Gifts$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$29,990
Medicare patients
163
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ursodiol93$87,183
XifaxanRifaximin24$84,640
RezdiffraResmetirom20$75,335
Lactulose31$885
Azathioprine18$663
Gabapentin20$525
Albuterol Sulfate HfaAlbuterol Sulfate12$443
Levothyroxine Sodium21$217
Atorvastatin Calcium33$187
Lisinopril26$186
Potassium Chloride18$170
Rosuvastatin Calcium14$133
Prednisone22$133
Trazodone Hcl19$130
Amlodipine Besylate23$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$216$84,64024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →